Inpatient management of patients with volume overload and high filling pressures

Journal of Hospital Medicine

Volumn 3, Issue SUPPL 6, 2008, Pages

  Khan, Tariq ^a   Heywood, J Thomas ^a  

^a SCRIPPS CLINIC   (United States)

Author keywords

Acute decompensated heart failure; ADHF; Filling pressure; Renal function; Volume overload

Indexed keywords

ADENOSINE A1 RECEPTOR; DIURETIC AGENT; VASODILATOR AGENT; VASOPRESSIN DERIVATIVE;

ACUTE DISEASE; DRUG ANTAGONISM; DRUG EFFECT; EVIDENCE BASED MEDICINE; HEART FAILURE; HOSPITAL; HUMAN; MEDICATION THERAPY MANAGEMENT; PATIENT CARE; PRACTICE GUIDELINE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; STANDARD; ULTRAFILTRATION;

ACUTE DISEASE; DIURETICS; EVIDENCE-BASED MEDICINE; HEART FAILURE; HOSPITALS; HUMANS; MEDICATION THERAPY MANAGEMENT; PATIENT CARE MANAGEMENT; PRACTICE GUIDELINES AS TOPIC; RECEPTOR, ADENOSINE A1; RENIN-ANGIOTENSIN SYSTEM; ULTRAFILTRATION; VASODILATOR AGENTS; VASOPRESSINS;

EID: 61849119100     PISSN: 15535592     EISSN: 15535606     Source Type: Journal    
DOI: 10.1002/jhm.396     Document Type: Review

References (62)

1. Stevenson L. Tailored therapy to hemodynamic goals for advanced heart failure. Eur J Heart Fail. 1999; 1(3): 251-257.
2. Kannel WB, D'Agostino RB, Silbershatz H, Belanger AJ, Wilson PWF, Levy D. Profile for estimating risk of heart failure. Arch Intern Med. 1999; 159(11): 1197-1204.
3. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure [editorial]. J Am Coll Cardiol. 1992; 20(1): 248-254.
4. Adamson PB, Magalski A, Braunschweig F, et al. Ongoing right ventricular hemodynamics in heart failure: clinical value of measurements derived from an implantable monitoring system. J Am Coll Cardiol. 2003; 41(4): 565-571.
5. Binanay C, Califf RM, Hasselblad V, et al. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA. 2005; 294(13): 1625-1633.
6. Fonarow GC, Stevenson LW, Steimle AE, et al. Persistently high left ventricular filling pressures predict mortality despite angiotensin converting enzyme inhibition in advanced heart failure [abstract 2624]. Circulation. 1994; 90(4 pt 2): I-488.
7. Konstam MA, Gheorghiade M, Burnett JCJr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007; 297(12): 1319-1331.
8. Califf RM. Considerations in designing acute decompensated heart failure clinical trials. Available at:http://www.medscape.com/viewarticle/557964. Accessed September 2008.
9. Gheorghiade M, Konstam MA, Burnett JCJr, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA. 2007; 297(12): 1332-1343.
10. Chaparro S, Dittrich HC, Tang WHW. Rolofylline (KW-3902): a new adenosine A1-receptor antagonist for acute congestive heart failure. Future Cardiol. 2008; 4(2): 117-123.
11. Lal S, Murtagh JG, Pollock AM, Fletcher E, Binnion PF. Acute haemodynamic effects of frusemide in patients with normal and raised left atrial pressures. Br Heart J. 1969; 31(6): 711-717.
12. Saxl R, Heilig R. The diuretic effect of Novasurol and other mercury injections. Wien Klin Wochenschr. 2002; 33: 943-944.
13. Fonarow GC, Heywood JT, Heidenreich PA, Lopatin M, Yancy CW. Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004: findings from Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2007; 153(6): 1021-1028.
14. Patel J, Smith M, Heywood JT. Optimal use of diuretics in patients with heart failure. Curr Treat Options Cardiovasc Med. 2007; 9(4): 332-342.
15. Monroy A, Plata C, Hebert SC, Gamba G. Characterization of the thiazide-sensitive Na(+)-Cl(-) cotransporter: a new model for ions and diuretics interaction. Am J Physiol Renal Physiol. 2000; 279(1): F161-F169.
16. Ellison DH. Diuretic therapy and resistance in congestive heart failure. Cardiology. 2001; 96(3-4): 132-143.
17. Dormans TPJ, Gerlag PGG. Combination of high-dose furosemide and hydrochlorothiazide in the treatment of refractory congestive heart failure. Eur Heart J. 1996; 17(12): 1867-1874.
18. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999; 341(10): 709-717.
19. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003; 348(14): 1309-1321.
20. Adams KFJr. Pathophysiologic role of the renin-angiotensin-aldosterone and sympathetic nervous systems in heart failure. Am J Health Syst Pharm. 2004; 61( suppl 2): S4-S13.
21. Hauben M, Reich L, Gerrits CM, Madigan D. Detection of spironolactone-associated hyperkalaemia following the Randomized Aldactone Evaluation Study (RALES). Drug Saf. 2007; 30(12): 1143-1149.
22. Eshaghian S, Horwich TB, Fonarow GC. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol. 2006; 97(12): 1759-1764.
23. Chuen MJNK, MacFadyen RJ. Dose-dependent association between use of loop diuretics and mortality in advanced systolic heart failure. Am J Cardiol. 2006; 98(10): 1416-1417.
24. Fonarow GC, Adams KFJ, Abraham WT, Yancy CW, Boscardin WJ. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA. 2005; 293(5): 572-580.
25. Hasselblad V, Gattis Stough W, Shah MR, et al. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail. 2007; 9(10): 1064-1069.
26. Loon NR, Wilcox CS, Unwin RJ. Mechanism of impaired natriuretic response to furosemide during prolonged therapy. Kidney Int. 1989; 36(4): 682-689.
27. Salvador DRK, Rey NR, Ramos GC, Punzalan FER. Continuous infusion versus bolus injection of loop diuretics in congestive heart failure. Cochrane Database Syst Rev. 2004; (1): CD003178.
28. López B, Querejeta R, González A, Sánchez E, Larman M, Díez J. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol. 2004; 43(11): 2028-2035.
29. Veeraveedu PT, Watanabe K, Ma M, et al. Comparative effects of torasemide and furosemide in rats with heart failure. Biochem Pharmacol. 2008; 75(3): 649-659.
30. Elkayam U, Janmohamed M, Habib M, Hatamizadeh P. Vasodilators in the management of acute heart failure. Crit Care Med. 2008; 36( suppl 1): S95-S105.
31. Hollenberg SM. Vasodilators in acute heart failure. Heart Fail Rev. 2007; 12(2): 143-147.
32. Elkayam U, Kulick D, McIntosh N, Roth A, Hsueh W, Rahimtoola SH. Incidence of early tolerance to hemodynamic effects of continuous infusion of nitroglycerin in patients with coronary artery disease and heart failure. Circulation. 1987; 76(3): 577-584.
33. Baines AD, DeBold AJ, Sonnenberg H. Natriuretic effect of atrial extract on isolated perfused rat kidney. Can J Physiol Pharmacol. 1983; 61(12): 1462-1466.
34. Abraham WT, Lowes BD, Ferguson DA, et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail. 1998; 4(1): 37-44.
35. Yoshimura M, Yasue H, Morita E, et al. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation. 1991; 84(4): 1581-1588.
36. Wang DJ, Dowling TC, Meadows D, et al. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine. Circulation. 2004; 110(12): 1620-1625.
37. Witteles RM, Kao D, Christopherson D, et al. Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre-existing renal dysfunction: a randomized, double-blind, placebo-controlled clinical trial. J Am Coll Cardiol. 2007; 50(19): 1835-1840.
38. Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med. 2000; 343(4): 246-253.
39. Publication Committee for the VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002; 287(12): 1531-1540.
40. Chang R, Elatre WA, Heywood JT. Effect of nesiritide on length of hospital stay in patients with decompensated heart failure. J Cardiovasc Pharmacol Ther. 2004; 9(3): 173-177.
41. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation. 2005; 111(12): 1487-1491.
42. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA. 2005; 293(15): 1900-1905.
43. Abraham WT. Serum creatinine elevations in patients receiving nesiritide are related to starting dose [abstract 248]. J Card Fail. 2005; 11( suppl 6): S156.
44. Riter HG, Redfield MM, Burnett JC, Chen HH. Nonhypotensive low-dose nesiritide has differential renal effects compared with standard-dose nesiritide in patients with acute decompensated heart failure and renal dysfunction. JAm Coll Cardiol. 2006; 47(11): 2334-2335.
45. Heywood JT. Combining nesiritide with high-dose diuretics may increase the risk of increased serum creatinine [abstract 2180]. Circulation. 2005; 112(17 suppl II): II-451-II-452.
46. Mentzer RMJ, Oz MC, Sladen RN, et al. Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery: the NAPA trial. J Am Coll Cardiol. 2007; 49(6): 716-726.
47. Chen HH, Sundt TM, Cook DJ, Heublein DM, Burnett JCJr. Low dose nesiritide and the preservation of renal function in patients with renal dysfunction undergoing cardiopulmonary-bypass surgery: a double-blind placebo-controlled pilot study. Circulation. 2007; 116( suppl 11): I-134-I-138.
48. Heywood JT. Temporal characteristics of serum creatinine elevations in patients receiving nesiritide and nitroglycerin [abstract 2793]. Circulation. 2008; 112(17 suppl II): II-590.
49. Abraham WT. Nesiritide does not increase 30-day or 6-month mortality risk [abstract 3169]. Circulation. 2005; 112(17 suppl II): II-676.
50. Yancy CW, Drum H, Massie BM, et al. Safety and efficacy of outpatient nesiritide in patients with advanced heart failure. Circ Heart Fail. 2008; 1: 9-16.
51. Costanzo MR, Guglin ME, Saltzberg MT, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2007; 49(6): 675-683.
52. Rogers HL, Marshall J, Bock J, et al. A randomized, controlled trial of the renal effects of ultrafiltration as compared to furosemide in patients with acute decompensated heart failure. J Card Fail. 2008; 14(1): 1-5.
53. Heart Failure Society of America. Evaluation and management of patients with acute decompensated heart failure. J Card Fail. 2006; 12(1): e86-e103.
54. Nohria A, Hasselblad V, Stebbins A, et al. Cardiorenal interactions: insights from the ESCAPE trial. J Am Coll Cardiol. 2008; 51(13): 1268-1274.
55. Forman DE, Butler J, Wang Y, et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol. 2004; 43(1): 61-67.
56. Boyle A, Sobotka PA. Redefining the therapeutic objective in decompensated heart failure: hemoconcentration as a surrogate for plasma refill rate. J Card Fail. 2006; 12(4): 247-249.
57. Heywood JT. The cardiorenal syndrome: lessons from the ADHERE database and treatment options. Heart Fail Rev. 2004; 9(3): 195-201.
58. Kumar S, Rubin S, Mather PJ, Whellan DJ. Hyponatremia and vasopressin antagonism in congestive heart failure. Clin Cardiol. 2007; 30(11): 546-551.
59. Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. J Am Coll Cardiol. 2005; 46(10): 1785-1791.
60. 1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation. 2002; 105(11): 1348-1353.
61. 1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment. J Card Fail. 2007; 13(8): 609-617.
62. Givertz MM, Massie BM, Fields TK, Pearson LL, Dittrich HC;CKI-201 and CKI-202 Investigators. The effects of KW-3902, an adenosine A1-receptor antagonist, on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance. J Am Coll Cardiol. 2007; 50(16): 1551-1560.